Literature DB >> 29165604

Carbapenemase-Producing Organisms: A Global Scourge.

Robert A Bonomo1,2, Eileen M Burd3,4, John Conly5,6, Brandi M Limbago7, Laurent Poirel8, Julie A Segre9, Lars F Westblade10,11.   

Abstract

The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern. Carbapenemase production is especially problematic when encountered in members of the family Enterobacteriaceae. Due to their ability to readily spread and colonize patients in healthcare environments, preventing the transmission of these organisms is a major public health initiative and coordinated international effort are needed. Central to the treatment and control of carbapenemase-producing organisms (CPOs) are phenotypic (growth-/biochemical-dependent) and nucleic acid-based carbapenemase detection tests that identify carbapenemase activity directly or their associated molecular determinants. Importantly, bacterial isolates harboring carbapenemases are often resistant to multiple antibiotic classes, resulting in limited therapy options. Emerging agents, novel antibiotic combinations and treatment regimens offer promise for management of these infections. This review highlights our current understanding of CPOs with emphasis on their epidemiology, detection, treatment, and control.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29165604      PMCID: PMC5884739          DOI: 10.1093/cid/cix893

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  58 in total

1.  Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae.

Authors:  Delphine Girlich; Laurent Poirel; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

2.  Detection of carbapenemase activity in Enterobacteriaceae: comparison of the carbapenem inactivation method versus the Carba NP test.

Authors:  Nathalie Tijet; Samir N Patel; Roberto G Melano
Journal:  J Antimicrob Chemother       Date:  2015-09-15       Impact factor: 5.790

3.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry meropenem hydrolysis assay with NH4HCO3, a reliable tool for direct detection of carbapenemase activity.

Authors:  Costas C Papagiannitsis; Vendula Študentová; Radoslaw Izdebski; Olga Oikonomou; Yvonne Pfeifer; Efthimia Petinaki; Jaroslav Hrabák
Journal:  J Clin Microbiol       Date:  2015-02-18       Impact factor: 5.948

4.  Characterisation of OXA-244, a chromosomally-encoded OXA-48-like β-lactamase from Escherichia coli.

Authors:  Anaïs Potron; Laurent Poirel; Laurent Dortet; Patrice Nordmann
Journal:  Int J Antimicrob Agents       Date:  2015-11-17       Impact factor: 5.283

Review 5.  From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling.

Authors:  G L Drusano
Journal:  Bioorg Med Chem       Date:  2016-08-27       Impact factor: 3.641

6.  Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM).

Authors:  Gaelle Cuzon; Thierry Naas; Pierre Bogaerts; Youri Glupczynski; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2012-05-17       Impact factor: 5.790

7.  Single-molecule sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae.

Authors:  Sean Conlan; Pamela J Thomas; Clayton Deming; Morgan Park; Anna F Lau; John P Dekker; Evan S Snitkin; Tyson A Clark; Khai Luong; Yi Song; Yu-Chih Tsai; Matthew Boitano; Jyoti Dayal; Shelise Y Brooks; Brian Schmidt; Alice C Young; James W Thomas; Gerard G Bouffard; Robert W Blakesley; James C Mullikin; Jonas Korlach; David K Henderson; Karen M Frank; Tara N Palmore; Julia A Segre
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

8.  Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.

Authors:  Alexandre Carpentier; Philippe Metellus; Renata Ursu; Sarah Zohar; Francois Lafitte; Maryline Barrié; Yuxia Meng; Margaretha Richard; Christophe Parizot; Florence Laigle-Donadey; Guy Gorochov; Dimitri Psimaras; Marc Sanson; Annick Tibi; Olivier Chinot; Antoine F Carpentier
Journal:  Neuro Oncol       Date:  2010-01-25       Impact factor: 12.300

9.  Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study.

Authors:  Mikhail V Edelstein; Elena N Skleenova; Oksana V Shevchenko; Jimson W D'souza; Dmitry V Tapalski; Ilya S Azizov; Marina V Sukhorukova; Roman A Pavlukov; Roman S Kozlov; Mark A Toleman; Timothy R Walsh
Journal:  Lancet Infect Dis       Date:  2013-07-09       Impact factor: 25.071

10.  Rapid detection of carbapenemase-producing Enterobacteriaceae.

Authors:  Patrice Nordmann; Laurent Poirel; Laurent Dortet
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

View more
  124 in total

1.  Diverse Vectors and Mechanisms Spread New Delhi Metallo-β-Lactamases among Carbapenem-Resistant Enterobacteriaceae in the Greater Boston Area.

Authors:  Nicole Pecora; Xiaomin Zhao; Kathleen Nudel; Maria Hoffmann; Ning Li; Andrew B Onderdonk; Deborah Yokoe; Eric Brown; Marc Allard; Lynn Bry
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Identification of the OXA-48 Carbapenemase Family by Use of Tryptic Peptides and Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Jeffrey R Strich; Honghui Wang; Ousmane H Cissé; Jung-Ho Youn; Steven K Drake; Yong Chen; Avi Z Rosenberg; Marjan Gucek; Patrick T McGann; John P Dekker; Anthony F Suffredini
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

3.  Rapid Identification of New Delhi Metallo-β-Lactamase (NDM) Using Tryptic Peptides and LC-MS/MS.

Authors:  John P Dekker; Anthony F Suffredini; Honghui Wang; Jeffrey R Strich; Steven K Drake; Yong Chen; Jung-Ho Youn; Avi Z Rosenberg; Marjan Gucek
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

4.  Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Authors:  Matteo Bassetti; Mura Akova; Mario Tumbarello
Journal:  Intensive Care Med       Date:  2018-09-28       Impact factor: 17.440

5.  Development and Application of a Core Genome Multilocus Sequence Typing Scheme for the Health Care-Associated Pathogen Pseudomonas aeruginosa.

Authors:  Richard A Stanton; Gillian McAllister; Jonathan B Daniels; Erin Breaker; Nicholas Vlachos; Paige Gable; Heather Moulton-Meissner; Alison Laufer Halpin
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

Review 6.  Past and Present Perspectives on β-Lactamases.

Authors:  Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from Enterobacteriales and Gram-negative non-fermenter bacteria by real-time PCR and melt-curve analysis.

Authors:  Massimo Mentasti; Kerry Prime; Kirsty Sands; Swati Khan; Mandy Wootton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-05       Impact factor: 3.267

Review 8.  Constructing and deconstructing the bacterial cell wall.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Protein Sci       Date:  2019-11-20       Impact factor: 6.725

9.  Multiple Copies of bla NDM-5 Located on Conjugative Megaplasmids from Porcine Escherichia coli Sequence Type 218 Isolates.

Authors:  Hong Yao; Aijuan Li; Runhao Yu; Stefan Schwarz; Huiyue Dong; Xiang-Dang Du
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 10.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.